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ABSTRACT  
 
Bacterial adhesion and subsequent biofilm formation on biomedical implants and devices are a major 
cause of their failure. As systemic antibiotic treatment is often ineffective, there is an urgent need for 
antimicrobial biomaterials and coatings. The term “antimicrobial” can encompass different 
mechanisms of action (here termed “antimicrobial surface designs”), such as antimicrobial-releasing, 
contact-killing or non-adhesivity. Biomaterials equipped with antimicrobial surface designs based on 
different mechanisms of action require different in vitro evaluation methods. Available industrial 
standard evaluation tests do not address the specific mechanisms of different antimicrobial surface 
designs and have therefore been modified over the past years, adding to the myriad of methods 
available in the literature to evaluate antimicrobial surface designs. The aim of this review is to 
categorize fourteen presently available methods including industrial standard tests for the in vitro 
evaluation of antimicrobial surface designs according to their suitability with respect to their 
antimicrobial mechanism of action. There is no single method or industrial test that allows to 
distinguish antimicrobial designs according to all three mechanisms identified here. However, critical 
consideration of each method clearly relates the different methods to a specific mechanism of 
antimicrobial action. It is anticipated that use of the provided table with the fourteen methods will 
avoid the use of wrong methods for evaluating new antimicrobial designs and therewith facilitate 
translation of novel antimicrobial biomaterials and coatings to clinical use. The need for more and 
better updated industrial standard tests is emphasized.   
  
 
Statement of Significance 
 
European COST-action TD1305, IPROMEDAI aims to provide better understanding of mechanisms of 
antimicrobial surface designs of biomaterial implants and devices. Current industrial evaluation 
standard tests do not sufficiently account for different, advanced antimicrobial surface designs, yet are 
urgently needed to obtain convincing in vitro data for approval of animal experiments and clinical 
trials. This review aims to provide an innovative and clear guide to choose appropriate evaluation 
methods for three distinctly different mechanisms of antimicrobial design: (1) antimicrobial-releasing, 
(2) contact-killing and (3) non-adhesivity. Use of antimicrobial evaluation methods and definition of 
industrial standard tests, tailored toward the antimicrobial mechanism of the design, as identified here, 
fulfill a missing link in the translation of novel antimicrobial surface designs to clinical use.  
 
 
Keywords: Biofilm, biomaterial-associated infection,  antimicrobial-releasing, contact-killing, non-
adhesive 
 
  
 4 
Graphical abstract  
 
 
 
 
 
 
 
  
  
 5 
Table of Contents 
 
1. Introduction 6 
2. Definition of antimicrobial activity and efficacy 9 
3. The choice of bacterial species and challenge number 10 
4. Sterilization and application of conditioning films prior to evaluation 13 
5. How dead are killed bacteria? 14 
6. Evaluation methods for antimicrobial surface designs 15 
6.1. Agar zone of inhibition methods 16 
6.2. Suspension methods 17 
6.3. Methods comprising a high area to volume ratio 18 
6.4. Adhesion-based methods  21 
6.5 Biofilm-based methods 23 
7. Concluding comments  24 
Acknowledgements 
 25 
 
  
 6 
1. Introduction 
Bacterial adhesion and subsequent biofilm formation on biomedical implants and devices are 
the main cause of their failure [1]. The incidence rates of biomaterial-associated infection (BAI) 
depend on the application considered, i.e. for urinary catheters the risk of acquiring an infection rises 
with 3–7% per day [2,3], central venous catheters (CVC) infections occur 2 to 4 times per 1000 CVC 
days [4,5], vascular prosthesis infection rates are between 0.5 and 5% [6], aortic endografts (stents) 0.2 
to 0.7% [7], total hip and knee arthroplasties have infection rates from 1% in primary replacements to 5% 
in revision surgery [8], while being higher for plates and screws in trauma patients [9] and infections 
rates for abdominal wall meshes range between 1% and 2% [10]. BAI is difficult to treat with 
antibiotics since bacteria are on the one hand protected by their biofilm mode of growth and on the 
other hand not effectively targeted by a compromised host immune system at the site of the implanted 
biomaterial or device [11–13]. Dental implants, though placed in an unsterile environment, have a 
relatively low infection rate of around 1% [14], suggested to be due to adaptation of the immune 
system to the presence of bacteria and biomaterials. BAI often requires surgical replacement of the 
implant or device, typically accompanied by great discomfort to the patient, loss of quality of life, and 
high treatment costs [15]. Not seldom, the difficulties associated with the proper diagnosis of BAI lead 
to severe morbidity and mortality [16]. For instance, cases with low-grade BAI can easily be 
misdiagnosed as a touch of the flu, with fatal consequences for patients [17].  
BAI develops frequently through transfer of commensal bacteria from the skin to an implant or 
device surface during surgery (“early per-operative contamination”) or hospitalization prior to 
complete wound closure (“late per-operative contamination”) [18]. Apart from the per-operative route, 
bacteria can reach the biomaterial surface through hematogenous spreading from infections elsewhere 
in the body [19]. Importantly, bacteria may survive in surrounding tissue even after revision surgery, 
posing novel requirements to treatment strategies [20]. Because therapeutic measures to control BAI 
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often fail and have severe consequences to the patient, emphasis has shifted to prevention of BAI by 
designing novel antimicrobial biomaterials or coatings for implants and devices [21].  
The term “antimicrobial” is rather loosely used in the current literature encompassing different 
mechanisms of action that, in one way or another, may contribute to the prevention of BAI. Three 
distinctly different mechanisms of antimicrobial action can be distinguished based on (1) surfaces that 
release antimicrobials, (2) surfaces that kill adhering bacteria directly upon adhesion without release of 
antimicrobials (contact-killing) (3) surfaces that are non-adhesive towards bacteria (non-adhesivity). 
(Note that we carefully avoid the more general term “antifouling”, because it is highly non-specific. 
“Fouling” refers to any unwanted deposition of material onto a surface, ranging from microorganisms 
on biomaterials implants and devices to barnacles and mussels in a marine environment, while “anti” 
encompasses all possible mechanisms that prevent or reduce fouling.) Local release of antimicrobials, 
like gentamicin and amoxicillin, from biomaterial beads or coatings has been applied in cardiovascular 
stents, surgical meshes, urinary catheters, orthopedic implants, or trauma devices [22–24]. In addition, 
antiseptics like chlorhexidine and silver sulfadiazine have been used in drug-releasing central venous 
catheters [25,26]. Antimicrobial-releasing coatings may be depleted when antimicrobial-release is most 
needed, while as a second drawback sustained low-level tail-release will contribute to the development 
of antibiotic-resistance [27]. Therefore contact-killing [28–33] and non-adhesive [34,35] surfaces are 
considered advantageous for long-term antimicrobial activity. Long-term efficacy of contact–killing 
surfaces, however, has been questioned because of a potential coverage of the surface by adsorbed 
proteins from blood, serum or other body fluids or development of a layer of dead bacteria [36]. Yet, 
efficacy of contact-killing quaternary ammonium-coated surfaces has been demonstrated over a time 
period of several days in rats [37] and up to a month in sheep [38]. Herewith contact-killing and non-
adhesive surfaces bear promise in applications where hematogenous spreading of bacteria forms a 
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long-term threat as for joint replacements [44], pace-makers or intravenous catheters which are under 
continuous risk of colonization by cutaneous or subcutaneous bacteria [45,46]. Surfaces that are non-
adhesive to bacteria however, are often also non-adhesive to tissue cells, making them less suitable for 
biomaterial implants and devices requiring tissue integration. Addition of RGD-peptides to a non-
adhesive polymer-brush, however, enhanced tissue cell attachment without affecting non-adhesiveness 
towards Staphylococcus aureus [39,40]. Thus recent advances go beyond the level of a single 
mechanism of antimicrobial action and comprise dual- or multi-functional antimicrobial coatings 
combining advantages of both releasing, non-adhesiveness and/or contact-killing designs with features 
to improve in tissue integration [39]. Also nanotechnology-based antimicrobial strategies are rapidly 
emerging [41-43], but these too can be classified as working according to either of the three 
mechanisms of action distinguished in this paper or combinations thereof.   
Many experimental antimicrobial surface designs for biomaterials or coatings reported in the 
literature never get translated to clinical use, mainly because industry requires simple, robust and cheap 
manufacturing processes for antimicrobial surface designs while regulatory agencies require costly, 
often statistically impossible, large clinical trials before allowing market introduction [44]. In addition, 
it becomes harder and harder to obtain approval for animal studies and in most countries approval for 
animal experiments is subject to convincing in vitro evidence of efficacy. This puts emphasis on the 
design of proper in vitro evaluation methods for antimicrobial surface designs, tailored towards specific 
mechanisms of action [45]. Available industrial standard evaluation tests (see Table 1) are mostly 
intended to assess the antimicrobial efficacy of non-medical products, such as chemical disinfectants 
and antiseptics for food and domestic appliances (European Standard, EN 13697), antibacterial plastics 
(International Organization for Standardization, ISO 22196) or for textiles with improved hygiene, odor 
control and protection from microbial attack and products for disinfection [46–48]. Industrial standard 
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evaluation tests often do not consider differences in antimicrobial mechanism of a design. Accordingly, 
many industrial standard tests have been modified over the past years, adding to the myriad of methods 
available in the literature to evaluate antimicrobial biomaterials or coatings. The aim of this review is to 
categorize fourteen presently available methods including industrial standard tests for the in vitro 
evaluation of antimicrobial surface designs for biomaterials implants and devices according to their 
specific antimicrobial mechanism of action. Suggestions are made for a comprehensive and versatile 
set of evaluation methods for specific antimicrobial surface designs, enabling cross-laboratory 
comparison. 
  
2. Definition of antimicrobial activity and efficacy  
In order to assess antimicrobial activity of biomaterials and coatings, a proper definition of the term 
“antimicrobial” is needed. “Antimicrobial” activity according to ISO 20743 is “the activity of an 
antibacterial finish used to prevent or mitigate the growth of bacteria, to reduce the number of bacteria 
or to kill bacteria”. The Japanese Industry Standard (JIS) defines “antimicrobial” in JIS Z 2801 as “the 
condition inhibiting the growth of bacteria on the surface of products”. Importantly, whereas ISO 
20743 mentions both growth inhibition and bacterial killing in their definition of antimicrobial activity, 
JIS Z 2801 only mentions growth inhibition. However, no distinction is made between killing and 
growth inhibition in their definition of antimicrobial activity. Both organizations judge the efficacy of 
antimicrobial products based on the difference in the logarithmic value of viable cell counts between 
antimicrobial test products and inert controls after incubation in the presence of a bacterial inoculum 
  
A = log (Ct/C0) – log(Tt/T0)        (Eq. 1a) 
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in which C0 and T0 are the challenge numbers of bacteria before incubation on the control and 
antimicrobial test sample respectively, while Ct and Tt are the number of bacteria obtained typically 
after 16 - 24 h incubation from the control and test sample respectively. Ideally, C0 and T0 should be 
equal numbers, although this is difficult to achieve when evaluating non-adhesive surfaces. In the ideal 
conditions, Eq. 1a reduces to its more well-known form 
 
A = log (Ct/Tt) = log(Ct) – log (Tt)       (Eq. 1b) 
 
Most available standard methods represented in Table 1 judge efficacy based on the value of 
antimicrobial activity according to Eq. 1b. It should be noticed however, that due to the use of a 
logarithmic scale, values for antimicrobial activity greatly depend on the bacterial challenge numbers 
applied: i.e. a log reduction of 2 involves a much larger reduction in bacterial numbers, when from 108 
to 106 than when from 104 to 102. Eq. 1b can also be applied in its linear, analogous form [28,49–52] in 
which case it reads  
 
            
  
  
              (Eq. 2) 
 
Antimicrobial activity values A can be evaluated purely on the basis of statistically significant 
differences, but from a microbiological perspective, including the criteria in JIS Z 2801, differences are 
only meaningful when more than two log-units or linearly expressed, more than 99% [53].  
3. The choice of bacterial species and challenge number 
The microbial species causative to BAI differ greatly among the different sites of functional restoration 
or support across the human body. Table 2 gives an overview of species causative to BAI of different 
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implants and devices. Many organisms causative to BAI are commensals of the skin, the intestines or 
the oral cavity, especially after short-term use of an implant or device. Opportunistic pathogens may 
become involved, especially after long-term use, such as Prevotella intermedia and Porphyromonas 
gingivalis in BAI associated with dental implants [59]. Infection after short-term use of urinary 
catheters is often due to Staphylococcus epidermidis, Escherichia coli or Enterococcus faecalis, while 
after long-term catheterization Pseudomonas aeruginosa, Proteus mirabilis and Klebsiella pneumoniae 
come into play [62,63]. In relation with studies into BAI and standard industrial tests, it is advisable to 
use well-known laboratory strains in combination with fresh clinical isolates. The use of laboratory 
strains offers the advantage of better allowing comparison of results obtained in different institutions 
and their specific properties are generally well studied. Compared with clinical isolates however, 
repeated culturing of laboratory strains may yield loss of their virulence, ability to produce EPS and 
form biofilms, including quorum sensing [64–66]. Many antimicrobial surface designs in the literature 
are not geared in their pre-clinical development stage towards a specific implant or device, in which 
case it is advisable to choose strains and species generally occurring in BAI. From Table 2, it is clear 
that such a collection of strains should minimally involve Gram-positive species such as S. aureus and 
S. epidermidis. Since the cell wall architecture of Gram-negative and Gram-positive bacterial strains 
differs considerably [67] with a possible impact on the efficacy of antimicrobial surface designs, at 
least one Gram-negative strain should be included too. Accordingly, in JIS Z 2801, it is suggested to 
use both a Gram-negative E. coli and a Gram-positive S. aureus. Depending on the application aimed 
for, pathogenic yeasts like Candida spp. should be included in the evaluation of antimicrobial surface 
designs, as they have antimicrobial susceptibilities that are very different from bacteria [68]. 
Antimicrobial biomaterials and coatings can be challenged with different numbers of 
microorganisms to evaluate their efficacy. Therapeutic antimicrobial surface designs are mostly applied 
when a patient shows clear signs of infection and a mature biofilm is present. Therapeutically aimed 
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antimicrobial surface designs such as antibiotic-loaded beads and spacers for the treatment of 
osteomyelitis [8,69,70] therewith face a much higher microbial challenge than designs aimed to 
prophylactically counteract the consequences of generally low levels of per-operative microbial 
contamination. In absence of well-documented data on the numbers of organisms clinically found on 
biomaterial implants and devices [71], industrial standard tests usually instruct to employ a defined 
inoculum that is expressed as the number of colony forming units (CFUs) per unit suspension volume, 
in which a material with a specified surface area is placed. Inoculum concentrations instructed in JIS Z 
2801 for instance (2.5 x 10
6 
CFU/mL), reflect the concentration of bacteria found in urine of patients 
with a catheter-associated-infection (10
5
 even up to 10
8 
CFU/mL [62]), but these bear no relation with 
the number of bacteria found on the catheter surface itself. In a measure of clinically relevant numbers 
of bacteria per unit area, the Infectious Diseases Society of America [72] states in its guideline on the 
diagnosis and management of intravenous catheter associated infections, that more than 100 CFUs on a 
5 cm catheter tip reflect catheter colonization. This would be roughly equivalent to 30 bacteria per cm
2
. 
However, much higher localized numbers, i.e. more than 10
6 
bacteria per cm
2
 (roughly equivalent to 
1% of full, bacterial mono-layer coverage), can be inferred from electron micrographs and fluorescent 
in situ hybridization images of biofilms on biomaterial implants and devices retrieved from patients 
with BAI [71,73–75], but these represent bacterial numbers found in clinical infections, rather than 
much lower initial per-operative bacterial contamination numbers. Moreover, bacteria involved in per-
operative contamination do not yet exhibit a mature biofilm architecture. Here too unfortunately, 
reliable numbers are absent. Typically, only less than 1 CFU per cm
2
 per hour is detected on a surface 
under a downward airflow in a ventilated operating theatre [76]. In other studies, 270 bacteria per cm
2 
of bacteria were found to contaminate a wound during surgery [77].  
 In summary, in the evaluation of antimicrobial surface designs, a challenge concentration 
should be applied that is in line with the intended application. Considering that most designs are 
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intended for prophylactic use, their evaluation against bacterial challenge numbers derived from 
biomaterial implants and devices retrieved from patients with clinical signs of infection, will put any 
prophylactically intended design at a disadvantage. Therefore we here suggest that antimicrobial 
surface designs intended to negate the potential development of infection arising from per-operative 
bacterial contamination, should be evaluated at challenge numbers of 1000 CFU per cm
2
 or less. 
Experimental conditions, especially in the evaluation of non-adhesive designs, often dictate working at 
concentrations of around 10
8
 bacteria per mL, which is far higher than observed for instance, in urine 
of patients with a catheter associated infection [62]. These considerations should be thoroughly taken 
into account in any evaluation method of antimicrobial surface designs. 
4. Sterilization and application of conditioning films prior to evaluation 
In most evaluation methods, antimicrobial surfaces are challenged by bacterial suspensions without 
further pre-treatment of the sample surfaces. Sterilization of biomaterials may leave residuals on their 
surface, affecting the surface chemistry designed. In the case ethylene oxide sterilization, such residuals 
can be irritating, mutagenic and at high  levels leading to organ damage and carcinogenicity [78]. 
Moreover, sterilization residuals may interfere with an antimicrobial surface design, regardless of its 
mechanisms [79,80].The relevance of evaluating sterilization effects is most evident in translational 
studies as sterilization is a prerequisite for implants or devices that are in direct contact with the human 
body. In particular safety aspects around ethylene oxide use are addressed in the ISO 10993 standard 
that guides biocompatibility evaluation of medical devices.  
Also, in nearly all clinical settings, biomaterial implants or devices are exposed to urine, saliva, tear 
fluid, sweat, blood, etcetera posing another challenge to antimicrobial surface designs affecting their 
surface chemistry. Adsorption of macromolecular components such as proteins from these body fluids 
proceeds much faster than adhesion of bacteria to form a so-called “conditioning film” [81]. Depending 
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again on the application aimed for, the potential presence of a conditioning film on an antimicrobial 
coating should be taken into account, as for instance many pathogens have specific receptors for 
salivary and blood-borne protein films [21,82–85]. Moreover, conditioning films may potentially 
impair the efficacy of antimicrobial-release and contact-killing designs [86,87].  
Conditioning films can also form during evaluation of antimicrobial surface designs, especially 
when the bacterial challenge originates from suspensions in culture medium. Tryptic Soy Broth, for 
instance, contains enzymatically digested soy bean proteins, whereas Nutrient Broth contains peptones 
of often undefined animal sources and beef extract. Culture media can also be supplemented with 
serum, from which many different proteins can sequentially adsorb to a sample surface [88]
 
prior to or 
during evaluation. Industrial tests provide conflicting instructions on the use of undiluted (e.g. AATCC 
100) or diluted (e.g. ISO 20743 and JIS Z 2801) culture media to suspend bacteria, which can 
subsequently lead to different evaluation results.  
Summarizing, it is suggested here that for evaluation of antimicrobial surface designs 
sterilization or application of an appropriate conditioning film geared to the application aimed for 
should always be taken into account.  
5. How dead are killed bacteria? 
There is a plethora of evaluation methods that have been developed and adapted to evaluate different 
antimicrobial surface designs, that at the end of the assay require enumeration of dead and live bacterial 
numbers. Whereas most methods are based on culturing and enumeration of the number of CFUs (see 
Figs. 1-3), many others include live/dead staining, fluorescence in situ hybridization (FISH), MTT 
(based on the reduction of the MTT dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
to the purple formazan by NAD(P)H) or use of bioluminescent strains to demonstrate bacterial death. It 
is beyond the scope of this review to extensively discuss the merits of the different methods to 
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demonstrate bacterial death. However, different types of antimicrobials can yield highly different types 
of damage to a bacterium with variable outcomes of a bacterial death quantification. Live/dead staining 
(e.g. LIVE/DEAD
®
 Bacterial Viability Kit (BacLight
TM
)) composed of two nucleic acid-binding stains: 
SYTO 9 (green-fluorescent) and propidium iodide (red-fluorescent) [89] in principle demonstrates the 
presence or absence of cell wall damage, but it has been shown that cell wall damaged, red-fluorescent 
bacteria usually presumed dead, may sometimes turn out to be culturable as well [90]. Bioluminescence 
and MTT heavily rely on metabolic activity, but absence of metabolic activity does not necessarily 
mean bacterial death. Moreover, with respect to culturing as the generally accepted “gold standard”, 
many bacterial strains are not culturable, while specific antimicrobials may bring bacteria in a 
reversible “dead” state, called “viable-but-not-culturable” or in an irreversible “dead” state, such as by 
lysis [91]. This makes demonstration of bacterial death one of the main challenges that microbiologists 
are facing across all fields of applications on a daily basis [92]. This challenge is extended greatly in 
the context of BAI. Bacteria in biofilms on biomaterials implants and devices are often subject to 
programmed cell death or the generation of a hibernation state such as in “persister” or “dormant” cells 
[93]. Due to their extremely low metabolic activity, persister or dormant cells are less susceptible to 
antimicrobials and easy to miss in death evaluation methods. With the ongoing discussion on when a 
bacterium can be declared death in absence of cell lysis as the most evident sign of death, it is advisable 
to evaluate bacterial death by culture based methods, extended with minimally one other method.  
6. Evaluation methods for antimicrobial surface designs 
In the forthcoming sections we will briefly describe the most common methods to evaluate 
antimicrobial surface designs, as schematically depicted in Figs. 1-3, in which we also indicate their 
suitability with respect to designs based on mechanisms of antimicrobial release, contact-killing or non-
adhesivity.  
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6.1. Agar zone of inhibition methods  
In agar zone of inhibition methods [27,47,94–98], samples are placed with their antimicrobial side 
down on an agar plate inoculated with microorganisms (see Fig. 1a.1). Possible antimicrobials released 
from a sample subsequently diffuse into the agar yielding a concentration gradient away from the 
sample. As long as the concentration in the agar is above the minimal inhibitory concentration (MIC), a 
zone in which bacterial growth is inhibited can be observed, the width of which is taken as a measure 
of antimicrobial activity. It is recommended that zones of inhibition be measured in different directions 
or locations, depending on the sample geometry. Typically, a 24 to 48 h incubation time is applied after 
which the width of the inhibition zone is measured, as a measure of both the amount of antimicrobial 
released and the susceptibility of the bacterial strain involved towards the antimicrobial. The method 
does not provide an antimicrobial activity value as defined in section 2, while it has been suggested that 
only a zone of inhibition with a minimal width of 10-15 mm indicates potential clinical significance 
[99].  
Several variations of the above exists, most notably including the regular transfer of samples to 
a freshly inoculated agar plate in order to study the kinetics of antimicrobial release [100]. Other 
variations include placing entire catheter sections in holes punched into the agar [26,101] or the use of 
3D agar molds to evaluate antimicrobial surface designs on real- or miniaturized implants or devices 
[102]. 
The zone of inhibition method is the most commonly used method for evaluating antimicrobial-
releasing designs. It can also be used for contact-killing designs by studying bacterial growth directly 
underneath a sample. Several industrial standard evaluation tests (see Table 1) relate with the zone of 
inhibition assay, in which inoculated agar is poured over an antimicrobial surface, implant or device 
before solidification, as e.g. in ASTM 2180 (see Fig. 1a.2). Although culturing on agar counts as the 
gold standard in antimicrobial evaluation, the method has as a drawback that not all bacterial strains 
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and species are culturable [103], while furthermore zones of inhibition may depend on the rate of 
diffusion of antimicrobials through the agar [104] 
6.2. Suspension methods  
In suspension methods such as ASTM E2149 [96,97,105–107], a known challenge number of 
microorganisms in a suspension volume is exposed to an antimicrobial-releasing sample for defined 
time periods after which the numbers of CFU in the suspension are assessed and related with those 
found for control samples (see Fig. 1b.1). Samples are placed in capped glass tubes containing a 
defined volume of a microbially inoculated suspension medium. After overnight growth under agitation 
at 37°C, aliquots are drawn from the suspension medium for agar plating and CFU counting [103,104] 
to facilitate calculation of the antimicrobial activity according to section 2. Drawback is the use of 
microorganisms in their planktonic state, in which they are much more susceptible to antimicrobials 
than organisms in their biofilm-mode of growth. Although optical density measurements are also done 
to asses antimicrobial activity  [42, 110], optical density reflects both live and dead bacteria without 
distinction. The sample area to fluid volume is critical in these methods and mostly small. This implies 
that the build-up of a high antimicrobial concentration may be slow or never occurring, particularly not 
when antimicrobial release is from coatings with low housing capacities.  
Immersion of porous, antimicrobially loaded materials such as textile fabrics [47] into a 
suspension, as in JIS L1902, SN 195924, AATCC 100, and ISO 20743 gives rise to a higher area to 
volume ratio (see Fig. 1b.2). Absorption of a bacterial suspension in growth medium into a porous 
material is allowed for a given period of time after which the suspension is removed, assuming bacteria 
remain entrapped in the medium absorbed in the pores. Next, porous samples are incubated, typically 
up to 24 h at 37°C, while entrapped bacteria become exposed to the antimicrobials released. After 
incubation, bacteria are removed from the porous material by vortexing or sonication followed by serial 
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dilution, agar plating and CFU enumeration and final calculation of antimicrobial activity. To prevent 
that possible antimicrobial release during vortexing or sonication influences bacterial viability, use of a 
neutralizing broth has been recommended in EN 1040 [105,111]. 
Suspension methods are also advocated like in ASTM E2149, to evaluate bacterial contact-
killing designs. In such an application of suspension methods, a contact-killing surface is placed in a 
suspension volume under shaking. Bacterial killing upon contact or adhesion to the sample surface is 
enumerated from reductions in the number of viable bacteria in suspension. Extensive experimental 
comparison of methods geared towards evaluation of contact-killing designs has shown this method to 
be unsuitable for evaluation of contact-killing surfaces, as mass-transport towards the surface is poorly 
controlled and usually small [112]. 
 
6.3. Methods comprising a high area to volume ratio  
Suspension methods are generally carried out at small (sample) area to (fluid) volume ratios, which, 
pending on the clinical application aimed for, is not always a realistic clinical scenario. This can have a 
severe impact in the evaluation of antimicrobial-releasing designs. Therefore a variety of methods has 
been developed that allows to work under conditions of high area to volume ratios enabling the rapid 
build-up of a high concentration of antimicrobials in case of antimicrobial-releasing designs.  
In JIS Z 2801 or ISO 22196, high area to volume ratios are established by sandwiching a 
microbial suspension in 0.2% medium between a sample surface and a cover slip, confining the 
suspension by capillary forces to around 250 μm thickness (see Fig. 2.1). After incubation for 24 h, 
bacteria are retrieved by sonication or extensive washing of both the sample material and the cover slip, 
and subsequently cultured on agar plates followed by enumeration to yield antimicrobial activities 
according to section 2 [112-116]. For the evaluation of antimicrobial-releasing bone cements, it has 
been suggested to grow bacteria in small gaps, cut in the cement. Importantly, bacteria surviving 
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antimicrobial-release from bone cements in suspension methods with a small area to volume ratio, were 
killed in a gap model [117]. 
The Petrifilm

 all-in-one-plating system (3M, St. Paul, MN, USA) [39,112,118-120] originally 
developed for fast screening of bacterial contamination of food products, is a commercial, ready to use 
system, consisting of a thin agar coat on a transparent foil that must be folded over a sample surface in 
presence of a small bacterially contaminated liquid volume of 20 - 50 μL (see Fig. 2.2). During an 
incubation time of up to 48 h at 37°C, bacterial colonies are formed. Apart from nutrients, the foil is 
also loaded with a stain (tetrazolium chloride) to visualize bacterial colonies that can subsequently be 
enumerated and used to calculate antimicrobial activity according to section 2 without any further 
processing. The combination of agar and stain in an all-in-one-plating method avoids washing or 
sonication and leaves relatively little waste. The possibility to enumerate bacteria implies applicability 
of antimicrobial activity values as defined in section 2, but cannot be directly applied when using high 
challenge concentrations or when the antimicrobial activity is low. In these cases the foil turns 
completed stained over the entire sample surface. This drawback can be circumvented for high 
challenge numbers by diluting the bacterial suspension from which challenge aliquots for inoculation 
are taken. By determining the number of CFUs of a diluted suspension on samples known to be non-
antimicrobial, challenge numbers in more concentrated challenge suspensions can then be easily 
calculated.   
The small volume of the all-in-one-plating method also enforces direct contact of bacteria with 
the sample, making the method not only suitable for antimicrobial-releasing but also for contact-killing 
designs. It has been strongly recommended however, that when an all-in-one-plating method is used for 
evaluating contact-killing surfaces, it should first be ascertained, for instance using a zone of inhibition 
method, that there are no antimicrobial components leaching out of the sample. Due to the small 
volume involved in an all-in-one-plating method, leachables may easily interfere with contact-killing 
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mechanisms. Also JIS Z 2801 has been suggested for evaluation of contact-killing designs [112,113]. 
In a slight modification of JIS Z 2801, a bacterially inoculated filter is placed on a contact-killing 
surface on which a 20 μL droplet is positioned containing 1% Tryptic Soy Broth after which the 
procedure is similar to the JIS Z 2801 test [121,122] (see Fig. 2.3). This so called “printing” of bacteria 
onto a sample to establish direct contact between a contact-killing surface and bacteria has also been 
prescribed in the ISO 20743 where a standard force of 4 N is applied to press the filter on a sample 
surface. The modified JIS method however, has yielded bacterial growth on surfaces, indicated in all-
in-one-plating and JIS Z 2801 methods as being contact-killing [112], possibly demonstrating more 
favorable conditions for bacterial growth in the sheltered environment of the filter, as applied in the 
modified JIS test. 
To evaluate contact-killing designs towards bacterial aerosols, spraying has been proposed 
[28,123,124] (see Fig. 2.4). This method was particularly applied to evaluate contact-killing surfaces 
that prevent growth of contamination by air-borne pathogens. After spraying a diluted bacterial 
suspension on test samples, samples are subsequently air-dried for 2 min at room temperature after 
which agar slabs of growth medium with the size of the sprayed surface are placed on top of the 
samples and covered with Parafilm
®
 to prevent their drying-out during overnight incubation. Bacterial 
colonies grown on the sample surfaces in the agar are counted by visual inspection without any further 
processing of the samples.  
In an extensive comparison of methods to evaluate bacterial contact-killing methods against 
Gram-positive and Gram-negative bacterial strains [112], it has been concluded that Petrifilm® all-in-
one-plating and JIS Z 2801 methods are most suitable to this end, provided that they are complemented 
with a zone of inhibition assay to exclude that leachables out of a sample add an additional killing 
mechanism.  
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6.4. Adhesion-based methods  
Adhesion of bacteria to a substratum surface is one of the first steps in biofilm formation. Methods to 
study initial bacterial adhesion usually involve adhesion of bacteria from a static or flowing fluid 
suspension. In static systems, mass transport of microorganisms to substratum surfaces mostly occurs 
through sedimentation [125], while in flow perfusion systems convective-diffusion contributes to mass 
transport. Since adhesion implies intimate contact between bacteria and substratum surfaces, adhesion-
based methods are excellently suited for evaluating contact-killing designs, especially because contact-
killing designs by cationic surfaces will yield electrostatic attraction of bacteria to the surface with an 
impact on adhesion numbers [126]. 
Static adhesion assays are relatively easy to carry out, e.g. test samples are exposed to a droplet 
of a bacterial suspension from which bacteria settle [50,127] (see Figs. 3a.1 and 3a.2) or are placed in 
well plates under mild shaking conditions [128] while keeping the number of bacteria allowed to 
sediment on a substratum surface below monolayer coverage in case of contact-killing designs. After a 
specific time period in which bacterial adhesion takes place, e.g. 1-4 h, the number of adhering viable 
bacteria is assessed by first carefully washing off all non-adhering bacteria, and then collecting 
adhering bacteria by sonication and subsequent CFU counting. By using live/dead staining of adhering 
bacteria, the ratio of killed bacteria can be determined by fluorescence microscopy. Alternatively, after 
careful washing off non-adherent bacteria, the sample is covered with a nutrient agar slab (see Fig. 
3a.2) and subsequently incubated. No steps to dislodge the bacteria are needed in this case, and 
individual viable bacteria adhering to the surface grow out as colonies, which are easily counted 
[92,129].  
Drawback of static assays is that enumeration requires washing off non-adherent bacteria, 
implying that removal of the fluid phase above the substratum should be done extremely careful in 
order to prevent inadvertent removal of adhering bacteria by passing liquid-air interfaces or flowing 
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fluid in general. Especially passing liquid-air interfaces are notorious for exerting high detachment 
forces on adhering bacteria causing their removal [130,131].   
Static adhesion-based methods are predominantly applied in testing antimicrobial-releasing or 
contact-killing surfaces, but are less well suited for anti-adhesive designs due to the lack of control of 
mass transport conditions and fluid flow forces operative during sedimentation and fluid removal. Flow 
perfusion methods not only allow to control mass transport, but also offer the possibility to accurately 
calculate the fluid flow forces on the adhering bacteria and fine-tune them to those occurring for 
instance in urinary catheters, vascular grafts, around artificial heart valves or extraluminal surfaces of 
cardiovascular catheters or to flow of therapeutic fluids as in intravenous catheters [132]. Different 
models of flow perfusion systems exist of which the parallel flow chamber is the most common one, 
particularly since fluid flow forces and mass transport are relatively easy to calculate (see Figs. 3a.3 
and 3a.4)  [125,133,134]. When combined with in situ observation of adhering bacteria, “washing” or 
“slight rinsing artefacts” can be fully avoided making the method extremely suitable to evaluate non-
adhesive antimicrobial designs to which bacteria usually adhere very weakly making them amenable to 
inadvertent removal. 
Flow perfusion systems are also highly suitable to evaluate contact-killing designs, in which 
case the flow of the bacterial suspension after the adhesion phase, is subsequently switched to a flow of 
nutrient media, that only allows surviving bacteria to grow out and form a biofilm from which bacteria 
are removed and analyzed by CFU counting and live/dead staining [135]. Alternatively, after the 
adhesion phase and after flushing out non-adherent bacteria, the chamber can be injected with live/dead 
stain after which fluorescence microscopy can directly be applied to obtain the antimicrobial efficacy 
of the sample (without exposing the adhering bacteria to a passing liquid-air interface) [136] (see Figs. 
3a.3 and 3a.4). Flow perfusion systems are less suitable to evaluate antimicrobial-releasing designs as 
the antimicrobials released are rapidly washed out of the system. In fact, growth of bacteria adhering to 
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antibiotic-releasing bone cements has been observed in flow perfusion systems, that was absent in 
static systems comprising a high area to volume ratio [137]. 
6.5 Biofilm-based methods  
Biofilm-based methods are in essence similar to adhesion-based methods but are carried out over much 
longer periods of time and must involve the presence of nutrients. Biofilm-based methods can rely on a 
plethora of different systems, that include all common static and flow perfusion systems, modified 
Robbins devices, drip flow reactors including the constant depth film reactor [139,140]  rotary biofilm 
reactors and microfluidic devices [103,141,142].  
All biofilm-based methods have to start with an adhesion step (see Fig. 3b), preferentially 
carried out from a low nutrient suspension as the presence of high nutrient concentrations in suspension 
eliminates the need for planktonic bacteria to adhere to a surface, where they “know” most nutrients 
accumulate [31,143]  a condition that they have in common with e.g. the JIS Z 2801 method. In the 
subsequent growth step, nutrient availability can be readily controlled in flow displacement systems 
which is important to avoid artefacts that might arise for instance from nutrient depletion of the 
environment in which biofilm growth of adhering bacteria is pursued. Biofilm-based methods seldom 
yield full eradication of biofilm by any antimicrobial design, and the best that can be achieved by any 
design is reduced amount of biofilm or delayed growth. In case of antimicrobial-releasing designs, 
growth inhibition or killing heavily depends on accumulation possibilities of antimicrobials released in 
the biofilm. This requires an appropriate biofilm structure that prevents wash-out of the antimicrobials, 
in which respect it is important to notice that biofilms grown in absence of any mechanical 
environmental stimulus such as under static conditions [31,144] (see Fig. 3b2), are usually fluffy and 
highly aqueous, which is opposed to biofilms grown in presence of applied compression or under fluid 
flow [145,146]. Since contact-killing surfaces seldom kill all adhering bacteria, biofilm-based methods 
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will always show biofilm growth on antimicrobial contact-killing designs [135]. Similarly, even on the 
most non-adhesive poly(ethylene)glycol polymer brush coating, bacteria have been demonstrated to 
adhere and form a biofilm very slowly, as compared to other surfaces [147]. This puts special emphasis 
on the inclusion of proper control surfaces in biofilm-based methods and the duration of time allowed 
for growth. Calculation of antimicrobial activity values according to Eq. 2  is well possible in most 
cases, but will decrease over time.  
 
7. Concluding comments  
This reviews clearly indicates (see Figs. 1-3), that there is no single method or industrial test that 
allows to distinguish antimicrobial designs according to the three mechanisms identified here. 
However, these figures clearly indicate that for each of the three antimicrobial mechanisms 
distinguished in this review, suitable methods are available. It is anticipated that use of this review will 
avoid the use of wrong methods for evaluating new antimicrobial designs and therewith facilitate 
downward clinical translation. Yet, further method standardization is needed. In particular, simple 
industry standards should be established that allow adhesion under flow conditions in which shear rates 
are quantifiable and in a range that complies with shear rates occurring in different clinical 
applications. In order to create the necessary high through-put, micro-fluidic systems [103, 141]  may 
become useful, although their versatility with respect to the materials that can evaluated is limited. 
Moreover, considering the development of multi-functional coatings [39] that are not only equipped 
with an antimicrobial functionality but also with tissue integrating moieties, academic developments of 
co-culture systems [148] should be standardized into industrial tests, preferably encompassing host 
immune cells as well [149]. In an era in which animal experiments become increasingly difficult to 
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obtain permission for [21,53], these standardizations are extremely important and may reduce the need 
for animal experiments. 
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Fig. 1. Schematics of agar zone of inhibition (a) and suspension (b) methods, as discussed in this review to 
evaluate the activity of antimicrobial surface designs, together with an indication of whether the method is 
identified as being suitable for antimicrobial surface designs based on release of antimicrobials, contact-killing 
or non-adhesivity. 
  
 
 
Fig. 2. Schematics of methods comprising a high area to volume ratio,  as discussed in this review to evaluate the 
activity of antimicrobial surface designs, together with an indication of whether the method is identified as being 
suitable for antimicrobial surface designs based on release of antimicrobials, contact-killing or non-adhesivity. 
 
  
Fig. 3. Schematics of adhesion (a) and biofilm (b) methods, as discussed in this review to evaluate the activity of 
antimicrobial surface designs, together with an indication of whether the method is identified as being suitable 
for antimicrobial surface designs based on release of antimicrobials, contact-killing or non-adhesivity. 
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Table 1. Industrial standard evaluation tests of antimicrobial surface designs and their possible relation 
with the different methods distinguished in Fig. 1, together with their intended application. (AATCC: 
American Association of Textile Chemists and Colorists, ASTM: American Society for Testing and 
Materials, EN: European Standard, ISO: International Standard Organisation, JIS: Japanese Industrial 
Standard, SN: Schweizerische Normen Vereinigung). 
Standard 
Application 
area 
AATCC 30  
Antifungal Activity, Assessment on Textile Materials 
Textiles/Fabrics 
AATCC 90 
Antibacterial Activity, Assessment of Textile Materials  
Textiles/Fabrics 
AATCC 100 
Assessment of Antibacterial Finishes on Textile Materials  
Textiles/Fabrics 
AATCC 147 
Antibacterial Activity Assessment of Textile Materials 
Textiles/Fabrics 
ASTM E2149 
Standard Test Method for Determining the Antimicrobial Activity of 
Antimicrobial Agents Under Dynamic Contact Conditions 
Textiles/Fabrics 
ASTM E2180-07 
Standard Test Method for Determining the Activity of Incorporated 
Antimicrobial Agent(s) In Polymeric or Hydrophobic Materials 
Non-porous 
materials 
ASTM E2722 
Standard Test Method for Using Seeded-Agar for the Screening 
Assessment of Antimicrobial Activity in Fabric and Air Filter Media 
Textiles/Fabrics 
EN 1104 
Paper and Board Intended to come into Contact With Foodstuffs - 
Determination of the Transfer of Antimicrobial Constituents 
 
Paper and board 
ISO 16869 
Assessment of the Effectiveness of Fungistatic Compounds in 
Plastics Formulations 
Plastics 
ISO 20645 
Textile fabrics - Determination of Antibacterial Activity  
Textiles/Fabrics 
ISO 20743 
Textiles-Determination of Antibacterial Activity of Antibacterial 
Finished Products 
Textiles/Fabrics 
ISO 22196 
Plastics – Measurement of Antibacterial Activity on Plastics 
Surfaces 
Non-porous 
materials 
JIS L 1902 
Testing for Antibacterial Activity and Efficacy on Textile Products 
Textiles/Fabrics 
JIS Z 2801 
Antimicrobial Products-Test for Antimicrobial Activity and Efficacy 
Non-porous 
materials 
SN 195920 
Textile Fabrics - Determination of the Antibacterial Activity  
Textiles/Fabrics 
SN 195924 
Textile Fabrics; Determination of the Antibacterial Activity 
Textiles/Fabrics 
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Table 2. Microbial species involved in BAI among different sites of functional restoration or support 
across the human body. 
  
Implant or device Species causative to BAI References 
Joint prostheses Staphylococcus aureus 
Staphylococcus epidermidis 
Streptococci  
[54] 
Vascular grafts Staphylococcus epidermidis 
Staphylococcus aureus 
[6] 
Central venous catheters Coagulase-Negative Staphylococci 
Enterococci 
Klebsiella pneumonia 
[55] 
Pace makers Coagulase-Negative Staphylococci 
Staphylococcus aureus 
[56] 
Contact lenses Pseudomonas aeruginosa 
Staphylococcus aureus 
Serratia marcescens  
[57] 
Biliary stents Enterococcus faecium  
Escherichia coli 
Enterobacter cloacae 
Klebsiella pneumonia 
[58] 
Dental implants Streptococcus mutans  
Streptococcus sanguinis 
Streptococcus mitis 
Actinomyces viscosus 
Prevotella intermedia  
Porphyromonas gingivalis  
[59,60] 
 
Abdominal wall meshes Staphylococcus aureus  
Streptococcus pyogenes 
Coagulase-Negative Staphylococci  
Escherichia coli 
[10] 
Voice prostheses Candida albicans 
Streptococci 
Staphylococcus epidermidis 
[61] 
Urinary catheters Escherichia coli 
Enterococci 
Klebsiella pneumoniae 
Coagulase-Negative Staphylococci  
Pseudomonas aeruginosa 
Candida albicans 
Proteus mirabilis 
[2,62,63] 
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Statement of Significance 
 
European COST-action TD1305, IPROMEDAI aims to provide better understanding of mechanisms of 
antimicrobial surface designs of biomaterial implants and devices. Current industrial evaluation 
standard tests do not sufficiently account for different, advanced antimicrobial surface designs, yet are 
urgently needed to obtain convincing in vitro data for approval of animal experiments and clinical 
trials. This review aims to provide an innovative and clear guide to choose appropriate evaluation 
methods for three distinctly different mechanisms of antimicrobial design: (1) antimicrobial-releasing, 
(2) contact-killing and (3) non-adhesivity. Use of antimicrobial evaluation methods and definition of 
industrial standard tests, tailored toward the antimicrobial mechanism of the design, as identified here, 
fulfill a missing link in the translation of novel antimicrobial surface designs to clinical use.  
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